UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026 (Report No. 5)
Commission File Number: 001-40753
ICECURE MEDICAL LTD.
(Translation of registrant’s name into English)
7 Ha’Eshel St., PO Box 3163
Caesarea, 3079504 Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
On November 19, 2026, IceCure Medical Ltd. (the “Company”) convened a Special General Meeting of Shareholders (the “Meeting”).
The Meeting was initially adjourned due to the absence of the required quorum present to open and conduct it at the initial time of 10:00 a.m. (Israel time). The Meeting was subsequently reconvened at 11:30 a.m. (Israel time). At the adjourned Meeting, a quorum was present, and Company’s shareholders approved the proposal described in the Company’s proxy statement for the Meeting, which was included as Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission (“SEC”) on November 2, 2026 (the “Proxy Statement”).
This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (File Nos. 333-298361, 333-270982, 333-264578, 333-262620 and 333-281587), filed with the SEC, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IceCure Medical Ltd. | |||
| Date: November 19, 2026 | By: | /s/ Eyal Shamir | |
| Name: | Eyal Shamir | ||
| Title: | Chief Executive Officer | ||
2